GlobalData on MSN9d
FDA grants orphan drug status to Arbor Biotechnologies’ PH1
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
BioWorld9d
Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).